Related Experiment Videos
Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report
Katarina Čular1, Dora Tomek Hamzić1, Ljiljana Smiljanić Tomičević2
1Department of Oncology, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Fibroblast growth factor receptor 2 (FGFR2) inhibitors, like pemigatinib, can cause calciphylaxis, a rare but fatal condition. Early recognition of skin lesions and prompt treatment cessation are crucial for patients with cholangiocarcinoma receiving these targeted therapies.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Fibroblast growth factor receptor 2 (FGFR2) inhibitors are targeted therapies for cholangiocarcinoma with FGFR2 alterations.
- While generally well-tolerated, these inhibitors can cause unique adverse events, including rare cases of calciphylaxis.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Chronic Kidney Disease II: Clinical Manifestations
Endocarditis IV: Nursing Management
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Peritoneal Dialysis III: Nursing Management